Abstract
Background
Acquired immune deficiency syndrome (AIDS) was first recognized by the United States Center for Disease Control (CDC) and Prevention in 1981 and its cause -Human immune deficiency virus (HIV) infection -was identified in the early part of the decade. 1 Genetic research indicates that HIV originated in the West -Central Africa during the late ninetieth or early twentieth century. 2 Since its discovery, AIDS has caused an estimated 36 million deaths worldwide. As of 2012, approximately 35.5 million people are living with HIV globally. 3 HIV/AIDS is considered a pandemic -a disease outbreak which is present over a large area and is actively spreading. HIV/AIDS has had a great impact on society, both as an illness and a source of discrimination. The disease also has significant economic impact. There are many misconceptions about it such as the belief that it can be transmitted by casual non-sexual contact. The disease has also become subject to many controversies involving religion. It has attracted medical and political attention as well as large scale funding since it was identified in the 1980s. 4 Since the first cases of HIV infection were identified, the number of children infected with HIV has risen dramatically in developing countries, the result of an increased number of HIV-infected women of child bearing age in these areas. Globally, between 2002 and 2013, there was a 58 percent reduction in the number of new HIV infection. Despite this, more than 240,000 children were infected with HIV during 2013. The figure below shows the number of children (defined by UNAIDS as under 15 years of age) directly affected 5 :
• 3.2 million children living with HIV around the world at the end of 2013.
• 240,000 children become newly infected with HIV in 2013.
• 58 percent drop in new infections since 2002, and a 43 percent drop in 2007.
• 91 percent of children living with HIV live in subSahara Africa.
• 24 percent of children needing antiretroviral treatment received in 2013. 
Definition
Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS) is a disease spectrum of the human immune system caused by infection with human immunodeficiency virus (HIV). 9 The term HIV/AIDS represents the entire range of the effects of infection which range from an often asymptomatic post infection stage to full-blown AIDS, with an array of opportunistic infections. 10
Etiopathogenesis
HIV is the cause of the spectrum of disease known as HIV/AIDS. HIV is a retrovirus that primarily infects components of the human immune system such as the CD4+ T cells, macrophages and dendritic cells. It directly and indirectly destroys CD4+ T cells. 11 HIV is a member of the genus Lentivirus, 12 which is transmitted as single stranded, positive-sense, enveloped virus. Upon entry into the target cells, the viral genome is converted (reverse transcribed) into double stranded DNA by a virally encoded reverse transcriptase. The resulting viral DNA is then imported into the cell nucleus and integrated into the cellular DNA by a virally encoded integrase and host cofactors. 13 Once integrated, the virus may become latent, allowing the virus and its host cell to avoid detection by the immune system. 14 Alternatively, the virus may be transcribed, producing new RNA genomes and viral proteins that are packaged and released from the cell as new virus particles that begin the replication cycle a new. 15 Two types of HIV have been characterized: HIV-1 and HIV-2. HIV -1 is the virus that was originally discovered. It is more virulent, infective , and is the cause of the majority of HIV infections globally. 16 After the virus enters the body, there is a period of rapid viral replication, leading to an abundance of virus in the peripheral blood. During primary infection, the level of HIV may reach several million virus particles per milliliter of blood. 17 This response is accompanied by a marked drop in the number of circulating CD4+ T cells. The acute viremia is almost invariably associated with activation of CD8+ T cells, which kill HIV-infected cells, and subsequently with antibody production, or seroconversion. 18 Ultimately, HIV causes AIDS by depleting CD4+ T cells. This weakene the immune system and allows opportunistic infections. 19 Although the symptoms of immune deficiency characteristic of AIDS do not appear for years after a person is infected, the bulk of CD4+ T cell loss occurs during the first weeks of infection, especially in the intestinal mucosa, which harbors the majority of the lymphocytes found in the body. 20 A vigorous immune response eventually controls the infection and initiates the clinically latent phase. CD4+ T cells in mucosal tissue remain particularly affected. 21 Continuous HIV replication causes a state of generalized immune activation which is reflected by the increased activation state of immune cells and release of proinflammatory cytokines. 22 Transmission HIV is transmitted by three main routes: sexual contact, exposure to infected body fluids of tissues, and from mother to child during pregnancy, delivery or breast feeding (known as vertical transmission). 23 There is no risk of acquiring HIV if exposed to feces, nasal secretions, saliva, sputum, sweat, tears, urine or vomitus unless they are contaminated with blood. 24 The viral load of an infected person is an important risk factor in both sexual and mother-to-child transmission. 25 In the absence of treatment, the risk of transmission before or during birth is around 20% and in those who also breastfed 35%. As of 2008, vertical transmission accounted for about 90% of cases of HIV in children. With appropriate treatment, the risk of mother-to-child infection can be reduced to about 10%. 26 
Classifications/ Types
Although most HIV-1 infected individuals have a detectable viral load and in the absence of treatment will eventually progress to AIDS, a small proportion (about 5%) retain high levels of CD4+ T cells without antiretroviral therapy for more than 5 years. These individuals are classified as HIV controllers or long term non-progressors. 27 Another group is those who also maintain a low or undetectable viral load, without antiretroviral treatment who are known as "elite controllers" or "elite suppressors". They represent approximately 1 in 300 infected persons. 28 
Clinical features
There are three main stages of HIV infection: acute infection, clinical latency and AIDS. 29 • Acute infection is the initial period following the contraction of HIV, also known as primary HIV or acute retroviral syndrome. 30 Many individuals develop an influenza like illness or a mononucleosis-like illness 2-4 weeks post exposure while others have no significant symptoms. 31 Symptoms occur in 40-90% of cases and most commonly include fever, large tender lymph nodes, throat inflammation, a rash, headache, and/or sores of the mouth and genitalias. 32 Some people also develop opportunistic infections at this stage. 33 Gastrointestinal symptoms such as nausea, vomiting or peripheral neuropathy or Guillain-Barr syndrome. Due to their non-specific character, these symptoms are not often recognized as signs of HIV infection. Thus, it is recommended that HIV be considered in people presenting an unexplained fever, who may have risk factors for the infection. 34 • there are a number of unique scientific and medical concerns that are important to consider in the treatment of children with HIV infection. These range from differences from adults in age-related issues such as CD4 lymphocyte counts and drug metabolism to requirements for special formation and treatment regimens that are appropriate for infants through adolescents. As in adults, treatment of HIV-infected children today is complex task of using potent combinations of antiretroviral agents to maximally suppress viral replication. Long term assessment of these children is also a high priority to assess sustained antiretroviral benefits as well as to monitor for potential adverse consequences of treatment 43 . Drug to treat HIV/AIDS use several different strategies, including:
• interfering with HIV's reproduction of its genetic material (called nucleoside or nucleotide antiretroviral).
• interfering with the enzymes HIV needs to take over certain body cells (protease inhabitors).
• interfering with HIV's ability to pack its genetic materials into viral code (non-nucleoside reverse transcriptase inhibitors,NNRTIS).
• newer types of medications (integrase inhibitors and CCR5 inhibitors) that use different strategies.
Because these drugs work in different ways, doctors generally prescribe a "combination cocktail" of these drugs that is taken everyday. Doctors also prescribe drugs to prevent certain opportunistic infections. Once treatment is begun, it is recommended that it is continued without breaks or holidays. The desired outcome of treatment is a long term plasma HIV-RNA count below 50 copies/ml.
Treatment consists of high active antiretroviral therapy (HAART) which slows progression of the disease. 44 Current HAART options are combinations consisting of at least three medications belonging to at least two types, or "classes" of antiretroviral agents. 38 Initially, treatment is typically a non-nucleoside reverse transcriptase inhibitor (NNRTI) plus two nucleoside analogue reverse transcriptase inhibitors (NRTIS). 45 Treatment recommendations for children are some what different from those for adults. The WHO recommends treating all children less than 5 years of age; children above 5 are treated like adults. 46 Measures to prevent opportunistic infections are effective in many people with HIV/AIDS. In addition to improving current disease, treatment with antiretroviral reduces the risk of developing additional opportunistic infections. 47 With respect to dietary advice and AIDS, some evidence has shown a benefit from micronutrient supplements. There is some evidence that vitamin A supplementation in children reduces mortality and improves growth. 48 Prognosis HIV/AIDS has become a chronic rather than an acutely fatal disease in many areas of the world. 49 Prognosis varies between people, and both the CD4 count and viral load are useful for predicted outcome. Without treatment, average survival time after infection with HIV is estimated to be 9 to 11 years, depending on the HIV subtype. After the diagnosis of AIDS, if treatment is not available, survival ranges between 6 and 19 months. 50 Half of the infants born with HIV die before two years of age without treatment. The primary causes of death from HIV/AIDS are opportunistic infections and cancer, both of which are frequently the results of the progressive failure of the immune system. Risk of cancer appears to increase once the CD4 count is below 500/µl. Tuberculosis co-infection is one of leading causes of sickness and death with HIV/AIDS being present in a third of all HIV infected people and causes 25% of all HIV related deaths. HIV is also one of the most important risk factors for tuberculosis. 51 Hepatitis C is another very common co-infection where each disease increase the progression of the other. 52 The two most common cancers associated with HIV/AIDS are Kaposi's Sarcoma and AIDS-related non-Hodgkin's lymphoma. 53 Even with antiretroviral treatment, over the long term HIV-infected people may experience neurocognitive disorders, osteoporosis, neuropathy, cancers, nephropathy and cardiovascular disease. It is not clear whether these conditions result from the HIV infection itself or are adverse effects of treatment. 54
Prevention
There is no effective vaccine for HIV or AIDS.
Comprehensive sexual education provided at school may decrease high risk behavior. 55 Treating people with HIV whose CD4 count >350 cells/µL with antiretroviral protects >96% of their partners from infection. Universal precautions within the health care environment are believed to be effective in decreasing the risk of HIV. 56 A course of antiretroviral administered with in 48 to 72 hours after exposure to HIV-positive blood or geneital secretions is referred to as postexposure prophylaxis. As of 2013, the prevention regimen recommended in the United States consists of three medications -tenofovir, contricitabine and raltegravir -as this may reduce the risk further. The duration of treatment is usually four weeks. The use of the single agent ziduvudine reduces the risk of a HIV infection five fold -following a needle stick injury. 57 Bangladesh responded early and decisively to the potential threat of HIV. In 1985, the Government of the Peoples Republic of Bangladesh established the National AIDS Committee (NAC) and mandated it to coordinate the response. In June 2010, the National strategic plan (NASP) established a steering committee to oversee the development of the NASP for HIV/AIDS 2011-2015. The goal set by the committee is to minimize the impact of AIDS on the individual, family, community and society. Of the strategies, the important one was to preventing Motherto-Child Transmission (PMTCT) of HIV6. UNAIDS 58 advocate for key strategies for preventing mother-to child transmission:
• keeping women of reproductive age and their partners HIV-negative through reproductive health and HIV prevention services.
• avoiding unwanted pregnancies among HIVinfected women and women at risk of HIV, through family planning and HIV testing and counselling services.
• ensuring HIV testing of pregnant women and timely access to effective antiretroviral therapy, both for the health of HIV-infected mothers, and for PMTCT, during delivery and breast feeding.
• better integration of HIV care, treatment and support for HIV-infected women and their families.
When an HIV-infected women is found to be pregnant, the following treatment plan to be implemented: 58 • before the birth of her baby: antiviral treatments given to the mother during pregnancy can help prevent HIV transmission to the baby.
• at the time of birth: antiviral medications can be given to both the mother and the newborn to lower the risk of HIV transmission that can occur during the birth process; in addition, the mother will be encouraged to formula-feed rather than the breast feed, because HIV can be transmitted to her baby through breast milk.
• during breast feeding: because breast feeding is discouraged among HIV-infected mothers, in places in the world with limited access to formula or clean water sypply to mix it, both the mother and the child can be treated with medications to lower the baby's risk of HIV infection.
When a child is born to a HIV-infected mother the following steps to be taken to prevent PMTCT: 6 • immediately after birth, neonates should get single dose of NVP within 72 hours of birth and AZT two times daily for 1-4 weeks, depending whether the mother took ART during pregnancy or not
• at 6 hours of age: all exposed babies should start taking CTX, this is the same drug that adults take to prevent pneumonia.
• ongoing: if the baby is HIV-infected, a CD4 test needs to be done; CD4% is a better measure in children under 5 years of age; babies should keep taking CTX until it is definite that they are not HIV-infected and they no longer breast feeding.
Programs to prevent the veritical transmission of HIV (from mothers to children) can reduce the rates of transmission by 92-99%. This primarily involves the use of a combination of antiviral medications during pregnancy and after birth in the infant and potentially includes bottle feeding rather breastfeeding. 52
Conclusion
HIV/AIDS is a global pandemic. The transmission of HIV from mothers to their infants contribute substantially to global morbidity and mortality for children under-5 years of age. HIV infection is often difficult to diagnose in very young children. Prevention of HIV infection remains of worldwide importance. It is vital that children who were infected via mother-tochild transmission receive treatment to keep them healthy. Cases of HIV infection and AIDS in children are complicated and should be managed by experienced health care professionals. It is also of utmost importance to do routine HIV testing and counselling of all pregnant woman.
